Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/21/2020 09/22/2020 09/23/2020 09/24/2020 09/25/2020 Date
69.26(c) 68.72(c) 67.16(c) 65.17(c) 69.47(c) Last
8 223 034 6 303 612 6 919 352 5 565 191 9 150 781 Volume
-0.87% -0.78% -2.27% -2.96% +6.60% Change
More quotes
Financials (USD)
Sales 2020 305 M - -
Net income 2020 -537 M - -
Net cash position 2020 2 553 M - -
P/E ratio 2020 -48,8x
Yield 2020 -
Sales 2021 4 870 M - -
Net income 2021 864 M - -
Net cash position 2021 3 655 M - -
P/E ratio 2021 31,7x
Yield 2021 -
Capitalization 27 412 M 27 412 M -
EV / Sales 2020 81,5x
EV / Sales 2021 4,88x
Nbr of Employees 975
Free-Float 80,1%
More Financials
Company
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows: - Collaboration revenue (79.8%); - Grant revenue (20.2%). At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and... 
More about the company
Notations Surperformance© of Moderna, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about MODERNA, INC.
09/25JOHNSON & JOHNSON, NIKE, ILLUMINA : Stocks That Defined the Week
DJ
09/25Johnson & Johnson COVID-19 vaccine produces strong immune response in early t..
RE
09/25Europe takes new action against Apple, Boeing’s 737 MAX flying soon?
09/24Health Care Down As Investors Hedge On Vaccine Chances -- Health Care Roundup
DJ
09/24Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial
RE
09/24Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial
RE
09/24EMERGINGGROWTH.COM : Why VBI Vaccines Could Be a Contrarian Investor's Dream
AQ
09/24China's Sinovac expects interim final-stage trial data on coronavirus vaccine..
RE
09/24EU close to concluding preliminary talks with Novavax on COVID vaccine supply..
RE
09/23Head of fda vaccine advisory committee steps aside over role in moderna trial..
RE
09/23Top adviser steps aside from FDA COVID-19 vaccine reviews over potential conf..
RE
09/23J&J kicks off study of single-shot COVID-19 vaccine in 60,000 volunteers
RE
09/23J&J kicks off study of single-shot COVID-19 vaccine in 60,000 volunteers
RE
09/23EU close to concluding preliminary talks with Novavax on COVID vaccine supply..
RE
09/23EU close to concluding preliminary talks with Novavax on COVID vaccine supply..
RE
More news
News in other languages on MODERNA, INC.
09/25WallStreet : remontée inattendue de +1,6%, espoir d'un vaccin
09/25COVID-19 : le Canada annonce un accord avec AstraZeneca
09/25EN DIRECT DES MARCHES : Lagardère, Suez, Total, BNP Paribas, Air France, Ales Gr..
09/24CORONAVIRUS : un onzième vaccin, par Novavax, entre en phase 3 d'essais clinique..
09/24BioNTech will nicht an Human-Challenge-Impfstoffstudie teilnehmen
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Stock Trading Strategies
MODERNA, INC. - 07/13
Buying pressure
BUY
More Stock Trading Analysis
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 91,47 $
Last Close Price 69,47 $
Spread / Highest target 92,9%
Spread / Average Target 31,7%
Spread / Lowest Target -41,0%
EPS Revisions
Managers
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.255.16%27 412
LONZA GROUP AG61.04%45 471
SEATTLE GENETICS, INC.61.87%32 181
CELLTRION, INC.42.82%29 371
IQVIA HOLDINGS INC.-2.08%28 939
IMMUNOMEDICS, INC.303.40%19 746